Inflammatory Markers Response To Citrulline Supplementation In Patients With Non-alcoholic Fatty Liver Disease: A Randomized, Double Blind, Placebo-controlled, Clinical Trial
Notes for this study:
||(pg/ml). Mean and SD Placebo: before 18.5 ± 2.04, after 17.4 ± 1.57. Citrulline: before 15.1 ± 4.74, after 14.6 ± 2.01.
|Number of Subjects
In this randomized, double-blind, placebo-controlled trial, 50 patients with NAFLD took 2 g of l-citrulline or placebo daily for 3 months.
83% of participants completed the study. There was a notably greater, statistically significant reduction in c-reactive protein and Nf-kb in the citrulline group compared with the placebo group, though there wasn't a notable difference for TNF-a. However, this didn't coincide with a notable difference in fibrosis or steatosis.